Session Type
Meeting
Search Results for Adverse event
Abstract Number: 408
SHM Converge 2023
Background: Timely, effective follow-up after hospital discharge can improve the efficiency and outcomes of care by increasing hospital throughput and decreasing readmissions and other adverse events after discharge. The University of Chicago Medical Center (UCMC) has chronic bed shortages and a medically and socially complex patient population that makes optimal management of post-discharge care especially […]
Abstract Number: 417
SHM Converge 2024
Background: Adverse events (AEs) occur in 19-28% of patients after discharge and can lead to unanticipated events, including emergency room visits and readmissions.(1,2) While early indicators include new and worsening symptoms (NWS), monitoring of patient-reported NWS is lacking. The 21st Century Cures Act mandates adoption of application programming interfaces (APIs), offering the potential to engage […]
Abstract Number: 582
Hospital Medicine 2019, March 24-27, National Harbor, Md.
Case Presentation: A 71-year-old woman with poorly differentiated squamous cell carcinoma (SCCA) of the left cheek with recent initiation of nivolumab therapy presented to the Emergency Department with five days of bilateral thigh pain, generalized weakness, and dyspnea. The exam was remarkable for tachycardia, hypotension, tachypnea as well as neck and proximal muscle strength weakness. […]
Abstract Number: 636
SHM Converge 2023
Case Presentation: This case describes a 63-year-old male who was recently diagnosed with renal cell carcinoma with metastasis to the lungs confirmed with a biopsy showing diffuse PAX-8 positivity on an immunohistochemical staining panel favoring renal origin. He was started on Nivolumab/Ipilimumab however was hospitalized in the intensive care unit for septic shock due to […]
Abstract Number: 703
SHM Converge 2021
Case Presentation: A 66-year-old female with metastatic small cell lung cancer involving brain, liver, and bones was admitted via ED with generalized weakness, mild confusion, and decreased oral intake for 3 days. She was initiated on immunotherapy with immune checkpoint inhibitors, ipilimumab (human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody) and nivolumab (a programmed death receptor-1 […]
Abstract Number: 745
Hospital Medicine 2019, March 24-27, National Harbor, Md.
Case Presentation: Case1: A 72- year old male with a diagnosis of stage four non-small cell Lung carcinoma who was treated with Pembrolizumab, presented two weeks after his first dose with generalized body aches and weakness. Labs showed elevated creatinine Kinase, increased serum creatinine with hyperkalemia to 5.6 and elevated troponins to as high as […]
Abstract Number: 786
SHM Converge 2023
Case Presentation: A 76-year-old female with a history of hypertension, BMI 48 kg/m2, hypothyroidism, and metastatic melanoma presented with a 2-week history of progressive myalgia, weakness, and dyspnea 3 weeks after the first infusion of nivolumab and relatlimab.In July 2019, she was diagnosed with stage IIB (cT4a, cN0, cM0) melanoma of the left leg (4.2 […]
Abstract Number: 837
SHM Converge 2023
Case Presentation: A 69-year-old male with a past medical history of urothelial carcinoma status post left nephrectomy began immunotherapy and was started on Atezolizumab. He developed bilateral lower extremity weakness that began following his first dose. After 3 doses, in 02/2022, his lower extremity weakness worsened to the point where he could not walk. A […]
Abstract Number: G23
SHM Converge 2022
Background: Communication related to medications is an important metric on the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey to measure patient experience after discharge from the hospital. There are many factors which can lead to poor communication about medications (Figure 1). Over 20% of readmissions can be related to medications, and of […]
Abstract Number: I11
SHM Converge 2022
Background: Opioid analgesia is an important treatment modality for patients with chronic pain, including pain attributed to cancer- and noncancer-related illness. Unfortunately, an estimated 40%–80% of opioid users experience opioid-induced constipation (OIC). Methylnaltrexone (MNTX) is indicated for the treatment of OIC. In clinical trials, the most common adverse events (AEs) were gastrointestinal (GI) in nature. […]